Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-26
2011-07-26
Solola, Taofiq A (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S050000
Reexamination Certificate
active
07985768
ABSTRACT:
The present invention relates to thiophene containing compounds of formula (I)wherein R1, R2, R3, and n are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.
REFERENCES:
patent: 6559186 (2003-05-01), Campbell
patent: 2008/0312435 (2008-12-01), Saito et al.
patent: 412404 (1991-02-01), None
patent: 568096 (1993-11-01), None
patent: 1219612 (2002-07-01), None
patent: 2796643 (2001-01-01), None
patent: WO-2005023818 (2005-03-01), None
patent: WO-2005058887 (2005-06-01), None
patent: WO-2006051704 (2006-05-01), None
patent: WO-2006070106 (2006-07-01), None
“IUPAC Commission on Nomenclature of Organic Chemistry Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry (Recommendations 1974),” Pure Appl Chem, 1976, 13-30, vol. 45.
Ambartsumova, R.F. et al., “Effect of Various Factors on the Reaction of 2-Aminobenzothiazoles with Propylene Oxide,” Chemistry of Heterocyclic Compounds, 2002, 994-999, vol. 38—Issue 8.
Ansell M.F. and Mason J.S., “The Synthesis of (+/−)-10a-Homo-11a-carbathromboxaneA1, a Stable Thromboxane A Analogue,” J Chem Soc Perkin Trans I, 1984, 1061-1068.
Arevalo-Martin, A., et al., “Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis,” Journal of Neuroscience, 2003, 2511-2516, vol. 23, No. 7.
Baker, T.J. et al., “Regiospecific Vinyl Phosphate/β-Keto Phosphonate Rearrangements Initiated by Halogen-Metal Exchange,” Journal of Organic Chemistry, 1998, 2613-2618, vol. 63—Issue 8.
Benito, C, et al., “A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis,” Journal of Neuroscience, 2005, 2530-2536, vol. 25—Issue 10.
Benito, C. et al., “Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains,” Journal of Neuroscience, 2003, 11136-11141, vol. 23—Issue 35.
Bouchard, J-F et al., “Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart”, Life Sciences, 2003, 1859-1870, vol. 72.
Boyle, W.J. et al., “Osteoclast differentiation and activation,” (Binary/Image), 2003, 337-342, vol. 423.
Brennan, T.J. et al., “Characterization of a rat model of incisional pain,” (Binary/Image), 1996, 493-501, vol. 64.
Buckley, N. E. et al., “Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB receptor,” European Journal of Pharmacology, 2000, 141-149, vol. 396.
Carlisle, S.J. et al., “Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation,” International Immunopharmacology, 2002, 69, vol. 2.
Carrier, E.J. et al., “Endocannabinoids in Neuroimmunology and Stress,” Current Drug Targets CNS and Neurological Disorders, 2005, 657-665, vol. 4.
Casanova, M.L. et al., “Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors,” Journal of Clinical Investigation, 2003, 43-50, vol. 111.
Chaplan, S.R. et al., “Quantitative assessment of tactile allodynia in the rat paw,” Journal of Neuroscience Methods, 1994, 55-63, vol. 53.
Cichewicz, D.L. et al., “Synergistic interactions between cannabinoid and opioid analgesics,” Life Sciences, 2004, 1317-1324, vol. 74.
Clayton, N. et al., “CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain,” (Binary/Image), 2002, 253-260, vol. 96.
Dixon, W.J. “Efficient analysis of experimental observations,” Annual Review of Pharmacology and Toxicology, 1980, 441-462, vol. 20.
Dorsch, J.B., McElvain, S.M., “The Preparation of Benzoylacetic Ester and Some of its Homologs,” J Am Chem Soc, 1932, 2960-2964, 54.
Fattori D., Henry S., Vogel P., “The Demjanov and Tiffeneau-Demjanov one-carbon ring enlargements of 2-aminomethyl-7-oxabicyclo[2.2.1]heptane derivatives. The stereo- and regioselective additions of 8-oxabicyclo[3.2.1]oct-6-en-2-one to soft electrophiles. ,” Tetrahedron, 1993, 1649-1664, 49/8, Pergamon Press Ltd.
Filippo, C.D. et al., “Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN,” Journal of Leukocyte Biology, 2004, 453-459, vol. 75.
Galiégue, et al., “Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations,” European Journal of Biochemistry, 1995, 54-61, vol. 232.
Golech, S.A. et al., “Human brain endothelium: coexpression and function of vannilloid and endocannabinoid receptors,” Molecular Brain Research, 2004, 87-92, vol. 132.
Greene, T.W. et al., “Protective Groups in Organic Synthesis”, 1999, 3 rd Ed, 494-653.
Grotenhermen, F. et al., “IACM 2nd Conference on Cannabinoids in Medicine,” Expert Opinion in Pharmacotherapy, 2003, 2367-2371, vol. 4—Issue 12.
Hanus, L. et al., “HU-308: A specific agonist for CB 2, a peripheral cannabinoid receptor,” Proceedings of the National Academy of Science, 1999, 14228-14233, vol. 96.
Hargreaves, et al., “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,” (Binary/Image), 1988, 77-88, vol. 32.
Hohmann, A.G. et al., “Selective Activation of Cannabinoid CB2 Receptors Suppresses Hyperalgesia Evoked by Intradermal Capsaicin,” Journal of Pharmacology and Experimental Therapeutics, 2004, 446-453, vol. 308.
Ibrahim, M.M. et al., “Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS,” Proceedings of the National Academy of Science, 2003, 10529-10533, vol. 100—Issue 18.
Ibrahim, M.M. et al., “CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids,” Proceedings of the National Academy of Science, 2005, 3093-3098, vol. 102—Issue 8.
Idris, A.I. et al., “Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors,” Nature Medicine, 2005, 774-779, vol. 11—Issue 7.
Ihenetu, K. et al., “Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids,” European Journal of Pharmacology, 2003, 207-215, vol. 458.
International Search Report for application No. PCT/US2007/0077321, Mailed on Jan. 2, 2008, 3 pages.
International Search Report, European Patent Office (Nov. 27, 2008).
Julien, B, et al., “Antifibrogenic Role of the Cannabinoid Receptor CB2 in the Liver,” Gastroenterology, 2005, 742-755, vol. 128.
Karsak, M, et al., “Cannabinoid receptor type 2 gene is associated with human osteoporosis,” Human Molecular Genetics, 2005, 3389-3396, vol. 14—Issue 22.
Kim, S.H. and Chung, J.M. “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,” (Binary/Image), 1992, 355-363, vol. 50—Issue 3.
Kreutzberg, G W “Microglia: a sensor for pathological events in the CNS,” Trends in Neuroscience, 1996, 312-318, vol. 19.
Lepicier, P. et al., “Endocannabinoids protect the rat isolated heart against ischaemia,” British Journal of Pharmacology, 2003, 805-815, vol. 139.
Lotersztajn, S. et al., “Hepatic Fibrosis: Molecular Mechanisms and Drug Targets,” Annual Review of Pharmacology and Toxicology, 2005, 605-628, vol. 45.
Malan, T.P. et al., “CB2 cannabinoid receptor-mediated peripheral antinociception,” (Binary/Image), 2001, 239-245, vol. 93.
Latshaw Steven P.
Nelson Derek W.
Abbott Laboratories
Gettel Nancy J.
Parial Andrew M.
Solola Taofiq A
Srivastava Soanli
LandOfFree
Compounds as cannabinoid receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as cannabinoid receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as cannabinoid receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648112